← Back to Search

Antisense Oligonucleotide

ARO-APOC3 for Dyslipidemias (MUIR Trial)

Phase 2
Waitlist Available
Research Sponsored by Arrowhead Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 36, week 48
Awards & highlights

MUIR Trial Summary

This trial is testing a new drug to see if it is safe and effective. Participants will be randomly assigned to take the drug or a placebo, and will be monitored for 48 weeks. Those taking the placebo will be given the option to take the drug during an extension study.

Eligible Conditions
  • Mixed Dyslipidemias

MUIR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 36, week 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 36, week 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24
Secondary outcome measures
Change from Baseline in Plasma Concentrations of ARO-APOC3 Over Time
Number of Participants with Treatment- Emergent AEs and/or SAEs Through Week 48
Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Week 24
+14 more

MUIR Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: ARO-APOC3 50 mg, Day 1 and Week 24Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Group II: ARO-APOC3 50 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Group III: ARO-APOC3 25 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Group IV: ARO-APOC3 10 mg, Day 1 and Week 12Experimental Treatment1 Intervention
2 doses of ARO-APOC3 by subcutaneous (sc) injection
Group V: Placebo, Day 1 and Week 12 or Week 24Placebo Group1 Intervention
calculated volume to match active treatment by sc injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARO-APOC3
2019
Completed Phase 2
~700

Find a Location

Who is running the clinical trial?

Arrowhead PharmaceuticalsLead Sponsor
39 Previous Clinical Trials
4,605 Total Patients Enrolled
3 Trials studying Dyslipidemias
715 Patients Enrolled for Dyslipidemias

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study still looking for participants?

"That is correct, the online information from clinicaltrials.gov says that this study is still looking for participants. This trial was originally posted on September 28th 2021 and was updated August 2nd of this year. They are looking for a total of 320 patients at 25 different locations."

Answered by AI

In how many different medical clinics is this research study being conducted today?

"Currently, there are 25 enrolling sites including locations such as Houston, Boca Raton, and Fort Lauderdale."

Answered by AI

How many patients can join this clinical trial at most?

"The correct answer is that this clinical trial is still recruiting patients. This information can be found on clinicaltrials.gov, where the study was first posted on September 28th, 2021 and last updated on August 2nd, 2022. In total, 25 medical centres are participating in the 320-person recruitment drive."

Answered by AI

What is the likelihood of harmful side effects from ARO-APOC3?

"ARO-APOC3's safety is based on Phase 2 trial data, which only provides limited evidence; thus, it received a score of 2."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
Texas
How old are they?
18 - 65
What site did they apply to?
Research Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
2021. "Study of ARO-APOC3 in Adults With Mixed Dyslipidemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04998201.
~101 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top